Abstract: The present invention encompasses methods of identifying proteins and protein modifications of proteins specifically associated with a chromatin.
Type:
Grant
Filed:
June 19, 2015
Date of Patent:
November 29, 2016
Assignee:
BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Inventors:
Alan J. Tackett, Stephanie Byrum, Sean Taverna, Kevin Raney, Zachary Waldrip
Abstract: The present invention relates to a system, device, and method for the high throughput multiplexed detection of a wide number of compounds. The invention comprises of a microwell array coupled to a capture agent array to form a plurality of interfaces between a microwell and a set of immobilized capture agents. The set of capture agents comprises a plurality of distinguishable features, with each feature corresponding to the detection of a particular compound of interest. In certain embodiments, each microwell is configured to contain a single cell. The invention is therefore capable of performing a high throughput analysis of single cell profiles, including profiles of secreted compounds.
Abstract: The invention provides compositions, methods, and kits for diagnosing, monitoring, and otherwise characterizing a myopathy and for detecting the presence of autoantibodies in a biological sample.
Type:
Grant
Filed:
May 2, 2016
Date of Patent:
November 29, 2016
Assignee:
The Johns Hopkins University
Inventors:
Livia A. Casciola-Rosen, Lisa Christopher-Stine, Andrew Mammen, Antony Rosen
Abstract: The present invention provides assays for detecting and measuring the presence or level of anti-TNF? drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.
Type:
Grant
Filed:
July 21, 2014
Date of Patent:
November 29, 2016
Assignee:
Nestec S.A.
Inventors:
Sharat Singh, Shui Long Wang, Linda Ohrmund
Abstract: [Problem] To provide a method that efficiently produces antigen-specific monoclonal antibodies from a wide range of animal species, and to provide a new antigen-specific monoclonal antibody using this technique. [Solution] A nonhuman animal is immunized with a target antigen, lymph fluid or the like is collected from the immunized nonhuman animal, or lymph fluid or the like is collected from a human having antibodies to the target antigen, the collected lymph fluid or the like is combined with (1) a labeled target antigen and (2) a marker that can selectively binds to plasma cells and/or plasmablasts, and cells that have bound to (1) the labeled target antigen and (2) the marker are then selected.
Type:
Grant
Filed:
March 28, 2012
Date of Patent:
November 8, 2016
Assignee:
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA
Abstract: Herein is reported a method for the detection of a multispecific antibody in a sample, whereby the multispecific antibody is specifically bound by i) a first anti-idiotypic antibody binding to a first binding specificity of the multispecific antibody, and ii) by a second anti-idiotypic antibody binding to a second binding specificity of the multispecific antibody and the formed complex is determined.
Abstract: The present invention relates to a polypeptide carrying a human BNP(I-32) epitope according to Formula (I): a1-R1-X1-FGRKMDR-X2-R2-a2 as well as ligands specific of the FGRKMDR epitope.
Abstract: The presently-disclosed subject matter includes methods and devices for diagnosing, prognosing, and treating brain damage in a subject, including brain damage caused by stroke or a traumatic brain injury (TBI). The methods can comprise providing a sample obtained from the subject, exposing the sample to an antibody selective for a visinin-like protein, detecting the presence of a complex that includes the antibody and the visinin-like protein, and diagnosing and/or prognosing the subject as having brain damage if there is the presence of the complex. Embodied methods can also comprise administering a treatment for brain damage if the subject includes the presence of the visinin-like protein.
Type:
Grant
Filed:
July 31, 2014
Date of Patent:
November 1, 2016
Assignee:
University of Kentucky Research Foundation
Inventors:
Mark A. Lovell, Bert C. Lynn, Melissa A. Bradley-Whitman
Abstract: There is provided antibodies, epitopes and methods for detecting ubiquitinated polypeptides and ubiquitination sites in proteins. The antibodies recognize a fragment of ubiquitin that is created after samples are treated with the proteoloytical enzyme LysC (or LysN).
Abstract: A method for quantifying metallothionein protein isomers is described herein. Such metallothionein isomer protein quantification is useful for detecting and monitoring disease. As illustrated herein, protein quantification is a more accurate measure of metallothionein induction than is mRNA quantification.
Type:
Grant
Filed:
May 17, 2013
Date of Patent:
October 18, 2016
Assignee:
University of North Dakota
Inventors:
John B. Shabb, Aaron Mehus, Wallace Muhonen, Donald A. Sens, Scott Garrett
Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins that are particularly advantageous for quantifying the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
Type:
Grant
Filed:
November 9, 2015
Date of Patent:
October 18, 2016
Assignee:
Expression Pathology, Inc.
Inventors:
David B. Krizman, Wei-Li Liao, Sheeno Thyparambil, Todd Hembrough
Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.
Type:
Grant
Filed:
May 28, 2015
Date of Patent:
October 4, 2016
Assignee:
ZORA BIOSCIENCES OY
Inventors:
Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
Abstract: A method of preparing an epitope for a secondary antibody detected protein tag, comprising: constructing a expressing vector, comprising a nucleotide sequence for encoding the secondary antibody detected protein tag comprising at least one epitope selected from at least one primary antibody which is detected by corresponding secondary antibody; expressing the vector in a host cell; and obtaining the secondary antibody detected protein tag which is expressed in the host cell. Further, a method for constructing a protein molecular weight marker ladder, comprising constructing a plurality of recombinant protein tags with different molecular weights, wherein each the recombinant protein tag comprises at least one epitope of primary antibody. Besides, a secondary antibody detected protein tag comprises at least two peptide sequences of epitopes selected from primary antibodies of at least two different species.
Type:
Grant
Filed:
November 6, 2014
Date of Patent:
October 4, 2016
Assignee:
Kaohsiung Medical University
Inventors:
Tian-Lu Cheng, Steve Roffler, Wen-Wei Lin, I-Ju Chen
Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.
Type:
Grant
Filed:
May 14, 2015
Date of Patent:
October 4, 2016
Assignee:
ZORA BIOSCIENCES OY
Inventors:
Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riika Katainen
Abstract: The present invention provides methods for analyzing a target compound from a biological sample. In one aspect, a method for analyzing a target compound in a biological sample can comprise delivering a biological sample through an affinity column, the affinity column having a binding ligand coupled to a stationary structural support, wherein the affinity column has a high density of the binding ligand per the stationary structural support and wherein the binding ligand has been preselected to cause weak affinity separation zonal retardation of the target compound from the biological sample forming a target compound fraction and a biological sample fraction and detecting the target compound by mass spectrometry.
Abstract: A method for treating depression using a biomarker includes measuring a level of phosphoethanolamine in a blood sample collected from a subject, comparing the level of phosphoethanolamine in the blood sample with a predetermined threshold, in response to the level of phosphoethanolamine in the blood sample being below the predetermined threshold, determining that the subject requires a treatment for depression, and treating the subject determined to suffer from depression.
Abstract: The disclosure provides methods for characterizing a prostate cancer sample by detecting expression of ERG, PTEN or both, changes in which relative to a normal control are shown herein to be correlated with prostate cancer capsular penetration and more aggressive forms of prostate cancer. Such methods are useful for the prognosis of prostate cancer capsular penetration and for making treatment decisions in patients with prostate cancer that has penetrated the capsule. Also provided are kits that can be used with such methods.
Type:
Grant
Filed:
August 28, 2012
Date of Patent:
September 6, 2016
Assignees:
Ventana Medical Systems, Inc., The Arizona Board of Regents on behalf of the University of Arizona
Inventors:
Gary Pestano, Ray B. Nagle, Connie Cortez, Kristie A. Vanpatten, Amit M. Algotar
Abstract: With the intention of providing an antibody which does not bind to fibrinogen and which has a high affinity for and a high specificity to insoluble fibrin, it is found that a site comprising the amino acids at positions 231 to 246 of the fibrinogen B? chain and a site comprising the amino acids at positions 232 to 246 of the fibrinogen ? chain are bound to each other in a fibrinogen molecule. Further, it is shown that when fibrinogen is converted to insoluble fibrin, the binding is released, and these sites are exposed. It is also found that antibodies obtained by immunization with these sites do not bind to fibrinogen and have high affinity for and high specificity to insoluble fibrin.
Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.
Type:
Grant
Filed:
May 27, 2015
Date of Patent:
August 23, 2016
Assignee:
ZORA BIOSCIENCES OY
Inventors:
Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen